The Legal Framework for Research Peptides in France: What the 2026 Regulations Say
RUO, marketing authorization, unlicensed practice of pharmacy: what the French regulatory framework actually says about research peptides, and where retatrutide stands.
The regulatory status of research peptides is a frequently asked question — and a legitimately complex one. This article is strictly informative and does not constitute legal advice. The applicable framework evolves and depends on each individual situation; for any specific question, consult a legal professional.
The principle: sale for research purposes
In France, as in most European countries, the purchase, possession, and use of chemical and peptide compounds for scientific research purposes fall under a framework distinct from that of medicines. A peptide sold as a laboratory reagent is not subject to the same rules as a drug, provided three structuring criteria are met:
- the product is explicitly marketed for research (a "For Research Use Only" / RUO notice on every product page and every label);
- no medical claim is made (no therapeutic promise, no dosage intended for human use);
- the product is analytically documented (independent CoA per lot), an implicit requirement for serious scientific use.
This is the same framework that allows international academic suppliers (Sigma-Aldrich, Bachem, Tocris, MedChemExpress) to market thousands of research compounds without these being classified as drugs.
The critical distinction: "research" molecule vs. the active ingredient of an approved drug
The most important point of caution concerns molecules that are already the active ingredient of a drug with a marketing authorization in France or Europe. This is notably the case for:
- semaglutide (Ozempic®, Wegovy®, Rybelsus®);
- tirzepatide (Mounjaro®);
- somatropin / human growth hormone (Genotropin®, etc.).
For these specific molecules, selling under a "research" label does not change their actual regulatory status: marketing a drug's active ingredient outside the pharmaceutical distribution channel can be classified as unlicensed practice of pharmacy, regardless of the labeling applied to the product. This is why Peptinium Labs does not distribute these specific molecules.
Where does retatrutide stand in this framework?
Retatrutide is a different case: it is a molecule still in clinical development (phase 3 trials, TRIUMPH program), which to date has no marketing authorization in France, Europe, or the United States. There is therefore currently no corresponding pharmaceutical specialty that would make its sale comparable to that of a drug diverted from its distribution channel. Its availability as a research reagent falls under the same framework as any experimental molecule studied by academic laboratories prior to obtaining marketing authorization.
This situation is not fixed: if a marketing authorization were granted in the future, the applicable framework for the molecule would change. We update our practices in line with published regulatory developments.
What a serious supplier guarantees
Beyond legality alone, a trustworthy research peptide supplier can be recognized by several cumulative practices:
- a CoA per lot, issued by an independent third-party laboratory (see our article on reading a CoA);
- full traceability of the lot number, from synthesis to shipment;
- shipping from within the European Union, reducing customs risks and cold-chain disruption;
- the total absence of medical claims on product pages, advertising, or commercial communication;
- compliant invoicing and labeling ("RUO", no human dosage information).
What Peptinium Labs does not do
We make no recommendations for human use, no therapeutic dosage, and we do not distribute molecules that are the active ingredient of a drug authorized in France or Europe. Our reconstitution calculator is a deterministic mathematical tool intended for preparing research samples — it does not in any way constitute a prescription.